The currently available genetically engineered mouse models of angiosarcoma are driven by knockout of Notch pathway components or FoxO,170 or overactivation of the mTOR pathway, but these may not reflect findings in human angiosarcomas. The gene discussed is MTOR; the disease is angiosarcoma.